Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis-Reference-Cited by-同舟云学术

Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis

Published:2024 Issue: Volume: Page:
ISSN:2434-9186
Container-title:Global Health & Medicine
language:en
Short-container-title:GHM

Author:

Kimura Makiko¹,Nishikawa Tomoki¹,Shimakami Tetsuro¹²,Terashima Takeshi¹²,Horii Rika¹²,Fukuda Masako¹,Yoshita Mika¹,Takata Noboru¹²,Hayashi Tomoyuki¹²,Funaki Masaya¹,Nio Kouki¹,Takatori Hajime¹,Arai Kuniaki¹²,Yamashita Tatsuya¹²,Honda Masao¹,Tanaka Junko³,Kaneko Shuichi¹,Yamashita Taro¹

Affiliation:

1. Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.

2. WHO Collaborating Center for Viral Hepatitis and Liver Cancer in WPRO, Kanazawa, Ishikawa, Japan.

3. Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima City, Hiroshima, Japan.

Publisher

National Center for Global Health and Medicine (JST)

Link

https://www.jstage.jst.go.jp/article/ghm/advpub/0/advpub_2024.01008/_pdf

Reference39 articles.

1. 1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396:1204-1222.

2. 2. Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023; 8:332-342.

3. 3. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308:2584-2593.

4. 4. Kalidindi Y, Jung J, Feldman R, Riley T, 3rd. Association of direct-acting antiviral treatment with mortality among medicare beneficiaries with hepatitis C. JAMA Netw Open. 2020; 3:e2011055.

5. 5. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013; 58:1537-1547.